Phase 2 Head and Neck Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have a confirmed diagnosis of squamous cell carcinoma (a type of cancer) in the head and neck area — but not cancers starting in the nasopharynx, nasal cavity or sinuses, mouth, salivary glands, thyroid, or skin
• People whose cancer's original location is unknown, but who have visibly enlarged lymph nodes detected on scans, with tissue confirmation through biopsy
• People whose cancer is in the oropharynx (throat area) or of unknown origin, where a specific protein marker called P16 has tested negative
• People whose cancer is in the hypopharynx or voice box (larynx), regardless of their P16 test result
• People whose cancer is at a certain stage — not too advanced and with no sign of spread to distant parts of the body, based on a specialised scan called a PET/CT (confirm with trial site for exact staging details)
• People aged 18 or older
• People who have not previously received radiation therapy or chemotherapy for this head and neck cancer
• People whose primary tumour was surgically removed but who still have visibly enlarged lymph nodes detectable on scans
• People with a reasonable level of general physical functioning, as measured by a standard performance scale (confirm with trial site)
• People who have had a CT or MRI scan of the neck with contrast dye
• People whose blood test results within the past 30 days show the bone marrow is producing enough blood cells (specific minimum levels apply — confirm with trial site)
• People whose kidney function tests within the past 30 days meet the required minimum levels (specific thresholds apply — confirm with trial site; those with reduced kidney function may still be considered for a modified treatment approach)
• People whose liver function tests within the past 30 days meet the required minimum levels (specific thresholds apply — confirm with trial site)
• Women who could potentially become pregnant must have a negative blood pregnancy test within 14 days before joining
• People (or their legal representative) who are willing and able to provide informed consent before joining the trial

Who may not be able to join:

• People whose cancer originated in the nasopharynx, nasal cavity or sinuses, mouth, salivary glands, thyroid, or skin
• People whose cancer is at a more advanced stage (T4 or N3 classification — confirm with trial site)
• People who have previously had radiation therapy to the head or neck area
• People who have previously received chemotherapy specifically for this head and neck cancer (prior chemotherapy for a completely different, unrelated cancer may be acceptable — confirm with trial site)
• People who have had chemotherapy or radiation therapy of any kind within the past three years
• People who have had surgery to remove the same cancer, other than a biopsy or removal of the primary tumour while enlarged lymph nodes are still present on scans
• People who have had another type of invasive cancer in the past, unless they have been cancer-free for at least 3 years, or unless that previous cancer has a very high estimated cure rate (confirm with trial site)
• People who have another cancer occurring at the same time, outside the throat area (exceptions may be considered by the trial doctors — confirm with trial site)
• People who are pregnant or breastfeeding
• People with serious active health conditions, including:
  • Unstable chest pain or heart failure that required hospitalisation in the last 6 months
  • A serious heart attack (affecting the full thickness of the heart wall) in the last 6 months
  • An active serious bacterial or fungal infection currently being treated with intravenous antibiotics
  • A flare-up of a chronic lung condition, or another breathing problem, that required hospitalisation or would prevent participation in the trial within the last 30 days
  • Serious liver disease causing visible yellowing of the skin or eyes, or blood clotting problems

Important: Always verify eligibility with the trial site directly before applying.